Day: June 2, 2021

OPEC Fund Supports Post-COVID-19 African Infrastructure With $50m Loan to Africa Finance Corporation

first_img Twitter Previous articleTEXAS VIEW: Failure to fix vaccine registry haunts TexasTHE POINT: The pandemic has cast a spotlight on the lack of support for our health care system.Next articleVelodyne Lidar signe un accord de vente pluriannuel avec Emesent Digital AIM Web Support By Digital AIM Web Support – January 27, 2021 OPEC Fund Supports Post-COVID-19 African Infrastructure With $50m Loan to Africa Finance Corporation Facebook Facebook Pinterest TAGS  center_img Local NewsBusiness WhatsApp Pinterest Twitter WhatsApp VIENNA–(BUSINESS WIRE)–Jan 27, 2021– The OPEC Fund for International Development (the OPEC Fund) and Africa Finance Corporation (AFC) have signed a $50 million loan agreement to help finance and build infrastructure needed for Africa’s post-COVID recovery. This represents the first direct financing co-operation between the two institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210127005070/en/ The proceeds of the 10-year loan to AFC will help address the continent’s well-known infrastructure financing gap. The loan will also support increased financial flows to Africa and contribute to COVID-19 recovery efforts in African economies by freeing up government funds to meet urgent financing needs related to the pandemic. AFC President and CEO, Samaila Zubairu said: “AFC has been engaging development partners worldwide to find ways that we can act in concert to mobilize the funds necessary for Africa’s post-pandemic recovery and optimize efficient deployment. This loan is in line with AFC’s effort to support the development-vital infrastructure, from energy to transport and commerce, and to return Africa back to the path of sustainable growth and development. We are committed to working with the OPEC Fund and other partners as critical enablers of essential infrastructure development.” OPEC Fund Director-General Dr. Abdulhamid Alkhalifa said: “Africa’s urgent infrastructure financing needs have become even more pronounced since the onset of COVID-19. The pandemic has hampered economic growth and investment across the continent. Our support to AFC will help provide sustainable financing for infrastructure development to improve connectivity, transport, logistics, trade and the creation of jobs. We look forward to a long and productive partnership with AFC. By working with experienced regional partners, our development impact is amplified.” AFC is a financial institution with 28 member countries, established to provide financing and private sector-driven solutions for infrastructure, natural resources and industrial projects across Africa. To date, AFC has invested over US$8.4 billion in projects within 35 African countries. The OPEC Fund signed a cooperation agreement with AFC in 2017 and this loan marks the beginning of collaboration on the ground. About the OPEC Fund The OPEC Fund for International Development (the OPEC Fund) is the only globally mandated development institution that provides financing from member countries to non-member countries. The organization works in cooperation with developing country partners and the international development community to stimulate economic growth and social progress in low- and middle-income countries around the world. The OPEC Fund was established by the member countries of OPEC in 1976 with a distinct mandate: to drive development, strengthen communities and empower people. Our work is people-centered, focusing on financing projects that meet essential needs, such as food, energy, infrastructure, employment (particularly relating to MSMEs), clean water and sanitation, healthcare and education. To date, we have approved more than US$25 billion for operations in 135 partner countries. Our vision is a world where sustainable development is a reality for all. About Africa Finance Corporation AFC was established in 2007 to be the catalyst for private sector-led infrastructure investment across Africa. It is the second highest investment grade rated multilateral financial institution in Africa. AFC’s approach combines specialist industry expertise with a focus on financial and technical advisory, project structuring, project development and risk capital to address Africa’s infrastructure development needs and drive sustainable economic growth. AFC invests in high-quality infrastructure assets that provide essential services in the core infrastructure sectors of power, natural resources, heavy industry, transport, and telecommunications. To date, the Corporation has invested over US$8.4 billion in projects in 35 countries across Africa. www.africafc.org View source version on businesswire.com:https://www.businesswire.com/news/home/20210127005070/en/ CONTACT: For more information, please contact: OPEC FUND: [email protected] Benamara OPEC Fund for International Development [email protected] +43 151 564138AFC/ NEW MARKETS CONTACT: Gavin Serkin New Markets Media & Intelligence [email protected] +44 20 3478 9710Olisa Nwokedi Africa Finance Corporation [email protected] +234 9062834707Rita Babihuga-Nsanze Africa Finance Corporation [email protected] +234 906 298 1490 KEYWORD: AFRICA EUROPE AUSTRIA INDUSTRY KEYWORD: BANKING PROFESSIONAL SERVICES FINANCE SOURCE: Africa Finance Corporation Copyright Business Wire 2021. PUB: 01/27/2021 04:00 AM/DISC: 01/27/2021 04:01 AM http://www.businesswire.com/news/home/20210127005070/enlast_img read more

Read More

Sypris Wins Awards From Two High-Pressure Energy Projects

first_img Pinterest TAGS  LOUISVILLE, Ky.–(BUSINESS WIRE)–Feb 8, 2021– Sypris Technologies, Inc., a subsidiary of Sypris Solutions, Inc. (Nasdaq/GM: SYPR), announced today that it has recently received orders for its Tube Turns® D-bolt and Tool-less® specialty closures for use in high-pressure oil and gas applications, including the Anchor Field development project in the Gulf of Mexico and the planned upgrade of a natural gas pipeline system in North America. Production for both awards will begin immediately and are expected to be completed prior to year-end. Terms of the purchases were not disclosed. The Anchor Field development project is located in the Green Canyon area, approximately 140 miles off the coast of Louisiana in the Gulf of Mexico in water depths of up to 5,000 feet. The initial development of the project will require an investment of approximately $5.7 billion. Stage 1 of the Anchor Field development consists of a seven-well subsea development and semi-submersible floating production unit. First oil is anticipated in 2024. According to news sources, this will be the first-ever, high-pressure development in the deepwater gulf. The planned facility has a design capacity of 75,000 barrels of crude oil and 28 million cubic feet of natural gas per day. Sypris will provide specialty, high-pressure Tube Turns® D-bolt closures that are rated up to 4,885 psi and use Inconel Alloy 625, a nickel-based superalloy that possesses high strength properties and resistance to elevated temperatures. The Company also received an award to supply the closures for a multiple compressor system upgrade on a natural gas transmission pipeline system located in North America. The project is part of an EPA program to reduce emissions from aging equipment to help reduce the negative impact on the ozone layer. Sypris will supply specialty Tube Turns® Tool-less® closures that are 72” in diameter, weigh 11.25 tons each and are rated to a pressure of 1,200 psi. Brett Keener, General Manager of Sypris Technologies, commented, “Sypris continues to be a leader in supplying engineered products to support major energy projects around the globe. We are able to meet the demanding requirements of these type of projects by leveraging our extensive experience in engineering and manufacturing high-quality products. We are proud to be a part of enhancing energy infrastructure and contributing to environmental protection.” Sypris Technologies, Inc. is a global leader in the manufacture of custom engineered closures for high-pressure, critical applications serving the oil and gas pipeline infrastructure, hydrocarbon and petrochemical processing, and utility industry since 1927. Headquartered in Louisville, Kentucky, the Company’s products are used worldwide, and can be found in projects ranging from the Trans-Alaska Pipeline and Strategic Petroleum Reserve in the U.S. to the Tengiz Oil Field in Kazakhstan and the Bonny Island Gas Field in Nigeria. For more information about the Company, visit its Web site at www.sypris.com. Forward Looking Statements This press release contains “forward-looking” statements within the meaning of the federal securities laws. Forward-looking statements include our plans and expectations of future financial and operational performance.Such statements may relate to projections of the company’s revenue, earnings, and other financial and operational measures, our liquidity, our ability to mitigate or manage disruptions posed by COVID-19, and the impact of COVID-19 and economic conditions on our future operations, among other matters. Each forward-looking statement herein is subject to risks and uncertainties, as detailed in our most recent Form 10-K and Form 10-Q and other SEC filings. Briefly, we currently believe that such risks also include the following: the impact of COVID-19 and economic conditions on our future operations; possible public policy response to the pandemic, including legislation or restrictions that may impact our operations or supply chain; our failure to successfully complete final contract negotiations with regard to our announced contract “orders”, “wins” or “awards”; our failure to achieve additional orders for existing projects; our failure to achieve and maintain profitability on a timely basis by steadily increasing our revenues from profitable contracts with a diversified group of customers, which would cause us to continue to use existing cash resources or other assets to fund operating losses; dependence on, retention or recruitment of key employees and distribution of our human capital; the cost, quality, timeliness, efficiency and yield of our operations and capital investments, including the impact of tariffs, product recalls or related liabilities, employee training, working capital, production schedules, cycle times, scrap rates, injuries, wages, overtime costs, freight or expediting costs; disputes or litigation involving governmental, supplier, customer, employee, creditor, product liability or environmental claims; our inability to develop new or improved products or new markets for our products; cost, quality and availability of raw materials such as steel, component parts, natural gas or utilities; our reliance on a few key customers, third party vendors and sub-suppliers; unanticipated or uninsured disasters, public health crises, losses or business risks; unanticipated or uninsured product liability claims; volatility of our customers’ forecasts, scheduling demands and production levels which negatively impact our operational capacity and our effectiveness to integrate new customers or suppliers, and in turn cause increases in our inventory and working capital levels; our inability to patent or otherwise protect our inventions or other intellectual property from potential competitors; adverse impacts of new technologies or other competitive pressures which increase our costs or erode our margins; legal rights to operate, manage our work force or import and export as needed; inaccurate data about markets, customers or business conditions; or unknown risks and uncertainties. We undertake no obligation to update our forward-looking statements, except as may be required by law. View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005056/en/ CONTACT: Brett H. Keener General Manager (502) 774-6271 KEYWORD: UNITED STATES NORTH AMERICA KENTUCKY INDUSTRY KEYWORD: OIL/GAS MANUFACTURING OTHER MANUFACTURING ENERGY ENGINEERING SOURCE: Sypris Technologies, Inc. Copyright Business Wire 2021. PUB: 02/08/2021 07:30 AM/DISC: 02/08/2021 07:30 AM http://www.businesswire.com/news/home/20210208005056/en Facebook By Digital AIM Web Support – February 8, 2021 WhatsApp Pinterest Facebookcenter_img Previous articleTumelo Skin Care Introduces So Sensitive! Body LotionNext articleMatterkind Expands Global Reach with Two Strategic Hires Digital AIM Web Support Sypris Wins Awards From Two High-Pressure Energy Projects Twitter Local NewsBusiness Twitter WhatsApplast_img read more

Read More

Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA…

first_img WhatsApp WhatsApp By Digital AIM Web Support – February 8, 2021 Facebook Facebook Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL Previous articleMcCormack helps unranked KU beat No. 23 Oklahoma St. 78-66Next articleCirelli scores twice as Tampa Bay beats Predators 4-1 Digital AIM Web Support BASEL, Switzerland–(BUSINESS WIRE)–Feb 8, 2021– Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, today announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NASDAQ:TGTX), has secured US FDA accelerated approval for the treatment of: adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen, andadult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. Accelerated approval was granted for these indications, under a priority review (MZL), based on the results of the Phase 2 UNITY-NHL Trial (NCT02793583); in MZL, an ORR of 49% with 16% complete responses and in FL an ORR of 43% with 3% complete responses were achieved, respectively. Umbralisib was earlier granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL. Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon and was discovered by Rhizen Pharma and subsequently licensed to TG Therapeutics (NASDAQ:TGTX) at an IND stage (TGR 1202) in 2012. In 2014, both parties entered into a licensing agreement as a part of which TGTX obtained worldwide rights and Rhizen has retained commercialization rights for India while also being the manufacturing and supply partner for Umbralisib. Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said: “Umbralisib’s approval offers MZL & FL patients a new treatment option and is a huge validation of Rhizen’s drug discovery & development capabilities. This is a momentous occasion in Rhizen’s journey as a successful biotech that speaks of the true ability of our team to discover & develop safe and effective therapies that can last the rigors of drug development. Further, we are keen to bring Umbralisib to Indian patients and we plan to initiate activities towards registration and approval there soon.” Pranav Amin, Chairman, Rhizen Pharmaceuticals & Managing Director of Alembic Pharmaceuticals Ltd said: “We are extremely proud of this historic milestone for Rhizen, and of the fact that Umbralisib is the first NCE discovered by Indian scientists to secure a US FDA approval. We are committed to working together with TG Therapeutics and Rhizen Pharma to ensure uninterrupted supply of UKONIQ™. Umbralisib is the first discovery asset to come out of Rhizen’s R&D efforts and this approval heralds the promise of the rest of Rhizen’s deep pipeline and continuing efforts.” About Umbralisib: Umbralisib is the first and only oral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon. PI3K-delta is known to play an important role in supporting cell proliferation and survival, cell differentiation, intercellular trafficking and immunity and is expressed in both normal and malignant B-cells. CK1-epsilon is a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies. Umbralisib is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. These indications are approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. More information on Umbralisib or UKONIQ™ can be found at https://www.tgtherapeutics.com/prescribing-information/uspi-ukon.pdf. About Alembic Pharmaceuticals Ltd: Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s products that are marketed through a marketing team of over 5000 are well recognized by doctors and patients. Information about Alembic can be found at http://www.alembicpharmaceuticals.com/. (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLL TD) (BSE: 533573) About Rhizen Pharmaceuticals A.G.: Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in Basel, Switzerland. For additional information, please visit www.rhizen.com. View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005742/en/ CONTACT: Samyukta Bhagwati Manager, Corporate Affairs & Communications Rhizen Pharmaceuticals AG +41 32 580 0113 [email protected] KEYWORD: EUROPE SWITZERLAND UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS SOURCE: Rhizen Pharmaceuticals AG Copyright Business Wire 2021. PUB: 02/08/2021 11:45 PM/DISC: 02/08/2021 11:45 PM http://www.businesswire.com/news/home/20210208005742/encenter_img Twitter Pinterest Twitter Pinterest TAGS  Local NewsBusinesslast_img read more

Read More

Fight over witnesses could delay Trump trial conclusion

first_img Twitter Twitter Local NewsUS News Fight over witnesses could delay Trump trial conclusion Jason Miller, Senior Adviser to the Trump 2020 re-election campaign, arrives at the Capitol on the fourth day of the second impeachment trial of Trump in the Senate, Friday, Feb. 12, 2021, in Washington. Pinterest By Digital AIM Web Support – February 13, 2021 Facebookcenter_img TAGS  Pinterest Facebook Previous articleHumphries in contention midway through monobob title raceNext articleImprisoned ex-FBI agent who worked with Bulger seeks release Digital AIM Web Support WhatsApp WhatsApplast_img read more

Read More

Insights on the Secure Web Gateways Global Market to 2027 – Featuring Citrix Systems,…

first_img Twitter Insights on the Secure Web Gateways Global Market to 2027 – Featuring Citrix Systems, Dell Technologies & IBM Among Others – ResearchAndMarkets.com By Digital AIM Web Support – April 6, 2021 Facebook TAGS  WhatsApp WhatsApp DUBLIN–(BUSINESS WIRE)–Feb 22, 2021– The “Secure Web Gateways – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The publisher brings years of research experience to the 8th edition of this report. The 139-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Global Secure Web Gateways Market to Reach $13.9 Billion by 2027 Amid the COVID-19 crisis, the global market for Secure Web Gateways estimated at US$3.7 Billion in the year 2020, is projected to reach a revised size of US$13.9 Billion by 2027, growing at a CAGR of 21% over the analysis period 2020-2027. Telecom & IT, one of the segments analyzed in the report, is projected to record a 21.6% CAGR and reach US$4.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the BFSI segment is readjusted to a revised 22.7% CAGR for the next 7-year period. The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 20.1% CAGR The Secure Web Gateways market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2027 trailing a CAGR of 20.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.9% and 18% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR. Government Segment to Record 20.2% CAGR In the global Government segment, USA, Canada, Japan, China and Europe will drive the 20% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$279.2 Million in the year 2020 will reach a projected size of US$999.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.7 Billion by the year 2027. Competitors identified in this market include, among others:Check Point Software Technologies Ltd.Cisco Systems, Inc.Citrix Systems, Inc.Dell TechnologiesIBM CorporationIntel Security Group – McAfee, Inc.Microsoft CorporationSophos Ltd.Symantec CorporationTrend Micro, Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEWGlobal Competitor Market SharesSecure Web Gateway Competitor Market Share Scenario Worldwide (in %): 2019 & 2025Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITIONTotal Companies Profiled: 46 For more information about this report visit https://www.researchandmarkets.com/r/eypr9i View source version on businesswire.com:https://www.businesswire.com/news/home/20210222005370/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/22/2021 04:36 AM/DISC: 02/22/2021 04:36 AM http://www.businesswire.com/news/home/20210222005370/encenter_img Twitter Pinterest Pinterest Facebook Local NewsBusiness Previous articleOpsCruise Emerges From StealthNext articleMogo Announces Closing of US$54 Million Registered Direct Offering Priced At-the-Market Digital AIM Web Supportlast_img

Read More